Gain new insights with CTCs — discover the AdnaTest LungCancer and ProstateCancerPanel AR-V7 kits


Circulating tumor cells (CTCs) are important in tumor dissemination. Molecular characterization of CTCs isolated from liquid biopsies can teach us about the biology of tumors cells, new molecular pathways, relevant biomarkers, the mechanisms of cancer progression and even tumor-therapy resistance. QIAGEN's new AdnaTest LungCancer and ProstateCancerPanel AR-V7 kits can give you added insights that may help you make your next big discovery!

In this webinar, we present the new AdnaTest LungCancer and ProstateCancerPanel AR-V7 kits.
The new AdnaTest ProstateCancerPanel AR-V7 detects splice variant AR-V7, an essential marker for therapy resistance to prostate cancer. This kit uses a immunomagnetic cell-selection system to enrich circulating tumor cells from human blood and to detect genes associated with prostate cancer, including AR-V7, using real-time PCR.

The new AdnaTest LungCancer Kit can be used to explore the molecular mechanisms of lung cancer through highly specific selection of CTCs in combination with a sensitive detection of a mix of targets associated with lung cancer. This kit detects the epithelial-to-mesenchymal transition, an important marker of cancer-therapy resistance, and specifically selects CTCs against a high leukocyte background, providing data that is easy to interpret.

Both AdnaTest kits are flexible enough to accommodate detection of alternative or novel biomarkers. Get easy, fast, highly accurate and reliable disease-status interpretation using only 5 ml of blood!

Constanze Kindler, Ph.D.

Constanze Kindler
 

Dr. Constanze Kindler joined QIAGEN in Hilden, Germany in 1993, where she held various positions in Sales and Global Marketing. She received her Ph.D. in Molecular Biology from the University of Münster in 1993. Dr. Kindler is currently an Associate Director, Global Product Management, Sample Technologies with a focus on Liquid Biopsy applications..